http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#Head http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#assertion http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#provenance http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#pubinfo http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#assertion http://purl.obolibrary.org/obo/DOID_2983 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_2983 http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00384 http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#association http://www.w3.org/2000/01/rdf-schema#label "Anuria. Severe or progressive kidney disease or dysfunction, with the possible exception of nephrosis. Severe hepatic disease. Hypersensitivity to the drug or any of its components. Triamterene capsules should not be used in patients with pre-existing elevated serum potassium, as is sometimes seen in patients with impaired renal function or azotemia, or in patients who develop hyperkalemia while on the drug. Patients should not be placed on dietary potassium supplements, potassium salts or potassium-containing salt substitutes in conjunction with triamterene capsules. Triamterene capsules should not be given to patients receiving other potassium-sparing agents, such as spironolactone, amiloride hydrochloride, or other formulations containing triamterene. Two deaths have been reported in patients receiving concomitant spironolactone and triamterene capsules or Dyazide (r) Abnormal elevation of serum potassium levels (greater than or equal to 5.5 mEq/liter) can occur with all potassium-sparing agents, including triamterene capsules. Hyperkalemia is more likely to occur in patients with renal impairment and diabetes (even without evidence of renal impairment), and in the elderly or severely ill. Since uncorrected hyperkalemia may be fatal, serum potassium levels must be monitored at frequent intervals especially in patients receiving triamterene capsules, when dosages are changed or with any illness that may influence renal function." http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#association https://w3id.org/biolink/vocab/relation https://schema.org/MedicalContraindication https://identifiers.org/drugbank:DB00384 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#provenance http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#pubinfo http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#sig http://purl.org/nanopub/x/hasSignature gN1roP4hiJIeLZHnl1xOfuTYh8RqYu6hj+bbrrCb15w3+8Wq7PY+l+ZEmRTy8gOabUnkTIqRwpXp4h6gApCjTJ3aE7lxK3oZ9koY/PscmlCIlbU4YR7ikHjaCgob2H6e3sD22heUJgPPUM5xkSlgSQRd8Hh71SoBrYzaC3NtJtQ= http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M http://purl.org/dc/terms/created 2021-08-23T18:45:03.617+02:00 http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RADqyKU-KpohccHSLZ-zsTQ2cU1RKQAH8EUYwejBfWI2M https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY